Primary polycythemia is classified as a syndrome with a chronic hematocrit elevation with low circulating erythropoietin (EPO) levels, consequently leading to an abnormal volume of red blood cells in the blood.
The frequency of Polycythemia in dogs is unknown and probably underestimated because it is often associated with nonspecific symptoms that can be attributed to various diseases.
Test specific information
The genetic factor is continuously present, and will always be visible.
The Turnaround Time (TAT) depends on various factors, such as the shipment time of your sample to the test location, the test method(s) and whether the tests are performed completely or partially by a Partner Lab or Patent owner.
The TAT of tests performed at our facilities is normally 10 working days after receipt of the sample at the testing laboratory (VHL, VHP or Certagen). For tests performed by a Partner Laboratory (so-called "partner lab test") or patent owner, the TAT is at least 20 working days after receipt of your sample. Because the shipment time to our Partner Labs or patent owner may vary due to factors we cannot influence, the mentioned 20 working days are therefore an estimate.
Sometimes it is necessary to re-run your sample. We call this a retest. In that case, the TAT will of course be extended.
Location of disease or trait
This disease affects the composition of the blood, consequently influencing the coagulation of blood.
For this test samples from all breeds are accepted.
For this DNA test we accept the following materials: Blood EDTA, Blood Heparin. Please contact Dr. Van Haeringen Laboratorium if you wish to submit other material as listed.
Somatic mutations will not be inherited to successive generations.
The analysed mutation in the canine JAK2 gene occurs as acquired somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. On the molecular level the mutation results in a constitutive activation of the Janus Kinase 2 (Tyrosine Kinase) and cytokine hypersensitivity which are responsible for the polycythemia. In humans, the identical mutation was identified in 90% of patients with polycythemia vera. Heterozygousity for this mutation is sufficient to produce the clinical picture of polycythemia, suggesting a dominant effect of the mutation.
Severity of Disease